Heart Association names RCE.ai to innovators’ network

As a winner of the American Heart Association’s annual Health Tech Competition, RCE.ai now has access to resources and capabilities through the Center for Health Technology & Innovation Innovators’ Network to advance new cardiac diagnostics that enable early assessment and appropriate risk stratification of patients with chestpain.


At the recent Heart Association Scientific Sessions 2023 in Philadelphia, Carlsbad, California-based RCE Technologies took center stage with the presentation of two prototypes that enable remote measurement and monitoring to aid in the diagnosis and treatment of myocardial heart injury.

The competition seeks innovations that have the potential to transform the landscape of heart and brain health. Entries must include, involve, or support the treatment of patients and solve an in-depth problem in the areas of antithrombotics, coronary artery disease/acute coronary syndrome, cardiometabolism, electrophysiology, heart failure, hypertension, imaging, lipids, resuscitation, stroke, surgery, or vascular medicine.

RCE produces non-invasive, immediate measurements of cardiac proteins in the blood – a non-invasive transdermal technique – to improve patient outcomes and reduce hospital stays and healthcare costs, according to the association’s announcement last week.

The jury selected RCE’s PyrAmes as the best business pitch and Cardiosense as the best scientific pitch, based on their validity, scientific accuracy and potential to improve patient outcomes, the association said.

The company will further develop its non-invasive, instantaneous measurement of cardiac proteins and virtual management of heart failure – including wearable sensors for immediate detection and pre-symptomatic detection – in collaboration with the consortium, which aims to reduce the costs of independently developing health technology decrease, according to the association. .

The jury assessed other technologies for the treatment and prevention of cardiovascular disease and stroke, developed by five finalists, which also included Ainthoven, based in Melbourne, Florida; CardieX, of Naperville, Ill.; Cardiosense in Chicago; and PyrAmes, based in Cupertino, California.


In July, RCE was included in the Cedars-Sinai Accelerator programa three-month program that offers companies $100,000 in funding and mentorship.

“The point-of-care trending of biomarker composition for acute cardiac injury may enable emergency room physicians and cardiologists in the early assessment and appropriate risk stratification of patients with chest pain,” RCE said.

Artificial intelligence and machine learning are being used to improve the detection of heart disease.

In 2022, the NHS began using AI to detect heart disease in 20 seconds while patients were in an MRI scanner. A British Heart Foundation-funded study published in the Journal of Cardiovascular Magnetic Resonance concluded that the ML had superior precision than that of three physicians.

Last year, the Mayo Clinic published a study in Nature where an AI-enabled electrocardiogram helped identify patients who had ‘slipped through the cracks’.

“The bottom line is that we will likely see more AI use in medicine over time,” says Dr. Peter Noseworthy, the Mayo Clinic cardiac electrophysiologist and senior author of the 2021 study.


Atandra Burman, founder and CEO of RCE Technologies, said in the statement that the company is focused on empowering healthcare professionals to provide the best patient care in real-time.

Andrea Fox is editor-in-chief of Healthcare IT News.
Email: afox@himss.org

Healthcare IT News is a HIMSS Media publication.